The lentivirus-containing short hairpin RNA (shRNA) targeting circHIPK3 was obtained from GenePharma (Shanghai, China), and the pLenti-GIII-CMV vector for circHIPK3 overexpression was obtained from Applied Biological Materials (ABM, Richmond, BC, Canada).
All shRNAs were transfected into the H9C2 cell lines. At 48 h post-transfection, the cells were selected with puromycin (2 µg/mL) for 2 weeks to construct cell lines with stable circHIPK3 knockdown or overexpression. The efficiency of transfection was verified by reverse transcription polymerase chain reaction (RT-PCR). The H9C2 cells were transfected with the abovementioned oligonucleotides and plasmids using Lipofectamine 3000/Invitrogen (Thermo-Fisher, Whaltham, MA, USA) according to the manufacturer’s instructions.
All shRNAs were transfected into the H9C2 cell lines. At 48 h post-transfection, the cells were selected with puromycin (2 µg/mL) for 2 weeks to construct cell lines with stable circHIPK3 knockdown or overexpression. The efficiency of transfection was verified by reverse transcription polymerase chain reaction (RT-PCR). The H9C2 cells were transfected with the abovementioned oligonucleotides and plasmids using Lipofectamine 3000/Invitrogen (Thermo-Fisher, Whaltham, MA, USA) according to the manufacturer’s instructions.